The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESC 2026 | Key priorities for achieving consistent cardiac amyloidosis care across Europe
Luuk Kieviet, MD, University Medical Center Utrecht, Utrecht, Netherlands, discusses key priorities for reducing variation in cardiac amyloidosis care across Europe. Dr Kieviet highlights persistent differences in diagnosis and treatment despite guideline recommendations, emphasizing the need to better understand infrastructure and resource-related factors to improve patient care and outcomes. This interview took place during the 2026 European Society of Cardiology (ESC) Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The key priorities are that we all are, or we made these surveys using ESC guidelines. So we use all the knowledge we have right now to identify and diagnose these patients and still, there are the differences and we want to know why, because the cardiologists say that in up to 90% they use these guidelines, so you should have the same time, and then we need to know what the differences in, maybe it’s infrastructure, maybe it’s money, because that will be another analysis that will be done as well...
The key priorities are that we all are, or we made these surveys using ESC guidelines. So we use all the knowledge we have right now to identify and diagnose these patients and still, there are the differences and we want to know why, because the cardiologists say that in up to 90% they use these guidelines, so you should have the same time, and then we need to know what the differences in, maybe it’s infrastructure, maybe it’s money, because that will be another analysis that will be done as well. So those are priorities because I think, and I think we all want this, that all patients in Europe should have the same options, actually. And not that, and mainly in Western Europe, you have an easier treatment path than in Eastern Europe, for instance. So we really want to have this equal in the whole of Europe. And I think that is really the key thing about this whole survey, but this whole study we’re doing. This is not only to improve for cardiac amyloidosis. This is really for the patients to help them get diagnosed earlier, to get treatment earlier, and to improve survival, quality of life, things like that. So in the end, it’s all for patient care, of course, and we’re really trying to put it into a path to visualize how treatment is now done, how diagnosis is done. And in that way, we hope that we can really make it equal for all countries in Europe.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
